Description
Book SynopsisThis book focuses on the drug discovery and development applications of transition metal catalyzed processes, which can efficiently create preclinical and clinical drug candidates as well as marketed drugs. The authors pay particular attention to the challenges of transitioning academically-developed reactions into scalable industrial processes. Additionally, the book lays the groundwork for how continued development of transition metal catalyzed processes can deliver new drug candidates. This work provides a unique perspective on the applications of transition metal catalysis in drug discovery and development it is a guide, a historical prospective, a practical compendium, and a source of future direction for the field.
Trade Review“The book will be particularly appreciated by young scientists, especially those aspiring to a future in the pharmaceutical industry, because it shows what kind of problems they will be asked to solve once they start their industrial career.” (ChemMedChem, 1 March 2013)
“All chapters are well-written and comprehensive with lots of examples from OPR and D. The book is highly recommended to all process chemists.” (Organic Process Research & Development Journal, 1 November 2012)
Table of ContentsPreface vii
Contributors ix
About the Authors xi
1 Transition Metal Catalysis in the Pharmaceutical Industry 1
Carl A. Busacca, Daniel R. Fandrick, Jinhua J. Song, and Chris H. Senanayake (Boehringer Ingelheim Pharmaceuticals)
2 Selected Applications of Transition Metal-Catalyzed Carbon–Carbon Cross-Coupling Reactions in the Pharmaceutical Industry 25
Hong C. Shen (Roche)
3 Selected Applications of Pd- and Cu-Catalyzed Carbon–Heteroatom Cross-Coupling Reactions in the Pharmaceutical Industry 97
Jingjun Yin (Merck)
4 Asymmetric Cross-Coupling Reactions 165
Vince Yeh (Novartis) and William A. Szabo (Consultant in Drug Development)
5 Metathesis Reactions 215
Oliver R. Thiel (Amgen)
6 Transition Metal-Catalyzed Synthesis of Five- and Six-Membered Heterocycles 257
Cheol K. Chung (Merck) and Matthew L. Crawley (Main Line Health)
7 Oxidative Catalysis 277
Lamont Terrell (GlaxoSmithKline)
8 Industrial Asymmetric Hydrogenation 315
Hans-Ulrich Blaser (Solvias)
Index 243
